0001209191-14-060604.txt : 20141001
0001209191-14-060604.hdr.sgml : 20141001
20141001172102
ACCESSION NUMBER: 0001209191-14-060604
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140930
FILED AS OF DATE: 20141001
DATE AS OF CHANGE: 20141001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEIDEN JEFFREY M
CENTRAL INDEX KEY: 0001242825
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 141133930
MAIL ADDRESS:
STREET 1: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-09-30
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001242825
LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2014-09-30
4
M
0
200000
29.98
A
344992
D
Common Stock
2014-09-30
4
S
0
24729
111.31
D
320263
D
Common Stock
2014-09-30
4
S
0
79817
112.21
D
240446
D
Common Stock
2014-09-30
4
S
0
53750
113.10
D
186696
D
Common Stock
2014-09-30
4
S
0
41704
113.90
D
144992
D
Common Stock
440
I
401(k)
Stock Option (right to buy)
29.98
2014-09-30
4
M
0
200000
0.00
D
2021-12-13
Common Stock
200000
213108
D
Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $111.31 (range $110.61 to $111.60).
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $112.21 (range $111.61 to $112.60).
Open market sales reported on this line occurred at a weighted average price of $113.10 (range $112.61 to $113.60).
Open market sales reported on this line occurred at a weighted average price of $113.90 (range $113.61 to $114.41).
The option vests in 16 quarterly installments from 12/14/2011.
Kenneth L. Horton, Attorney-In-Fact
2014-10-01